STAT3 and triple-negative breast carcinoma: Although few studies have published pharmacodynamic investigations of ruxolitinib in MBC, our results compare similarly with those of Stover et al., who reported on a limited subgroup of 3 subjects with metastatic triple-negative breast cancer that had received single-agent ruxolitinib and had paired pre-treatment and on-treatment tumor biopsies; they demonstrated incomplete suppression, with only a 40–55% decrease in phostpho-STAT3 with treatment14.